The positive effects of empagliflozin on renal disease are discussed by Dr Christoph Wanner, one of the lead authors of the EMPA-REG OUTCOME trial.

Pulmonary embolism in patients with syncope, TAVR via the carotid, LDL-C targets, caffeine, and episodes of atrial tachycardia are the topics discussed by Dr John Mandrola in this week's podcast.

ROCKET-AF controversy revisited, molecular autopsies, wrist heart-rate monitors, hypertension and cognition, and FDA warning on St Jude ICDs are discussed in this week's podcast.

More ROCKET-AF controversy, sodium restriction, biomarkers for stroke prediction, drugs on an FDA watch list and rivaroxaban vs dabigatran are discussed by Dr. John Mandrola in this week's podcast.

Biomarkers in patients with type 2 diabetes, coronary calcium and statin eligibility, tea and coffee, endovascular stroke therapy and healthcare reform are discussed in this week's podcast.

Dr Wharton reviews a common finding with unusual attributes. Have you seen it before?

PCSK9 inhibitors and plaque regression, hypotension and Entresto, digoxin in heart failure, pharmacist help with HF meds, sleep and CVD, and the statin debate are discussed this week.

Drs Harrington and Douglas discuss pay disparities for women in cardiology and the importance of leveling the playing field.

Dr Henry Black speaks with cardiologist Paul Thompson on how the best exercise practices are often the simplest

As various outlets, such as theheart.org | Medscape, cover new research presented at meetings, are you still motivated to show up in person?